The FDA Old Guard Backtracks on Rare Diseases—Again

Published



Once again officials within the FDA are proposing to put other interests over the needs of dying patients, predominantly children.

For more than three decades a group of FDA civil servants aligned with Ralph Nader’s Public Citizen has fought accelerated review of breakthrough drugs for devastating diseases. In the mid-1980s AIDS activists were the first to loosen the grip of this unholy alliance. Without the persistent campaigns of ACT UP and other activists, the FDA would not have approved the first AIDS treatment, AZT, in 1987. More significantly, the FDA’s accelerated approval of AZT stimulated the biotechnology industry to invest in better drugs; these drugs have not cured the disease, but they have saved millions of lives and made the disease manageable for many people.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.